

Product Update

lanthanum carbonate 750mg and 1000mg oral powder (Fosrenol®)
SMC No. (821/12)

Shire Pharmaceuticals Contracts Ltd

09 November 2012

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

lanthanum carbonate oral powder (Fosrenol®) is accepted for restricted use in NHS Scotland.

Indication under review: as a phosphate binding agent for use in the control of hyperphosphataemia in chronic renal failure patients on haemodialysis or continuous ambulatory peritoneal dialysis (CAPD).

Lanthanum is also indicated in adult patients with chronic kidney disease not on dialysis with serum phosphate levels ≥ 1.78 mmol/L in whom a low phosphate diet alone is insufficient to control serum phosphate levels.

SMC restriction: as a second-line agent in the control of hyperphosphataemia in chronic renal failure patients on haemodialysis or CAPD where a non-aluminium, non-calcium phosphate binder is required.

Lanthanum carbonate is as effective as calcium carbonate in reducing phosphate to target levels.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual

responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 10 September 2012.

**Chairman
Scottish Medicines Consortium**